18Sep

With the recent increase in hospitalizations and Covid-19 cases across the U.S. the question of How to protect ourselves and our loved ones from Covid lingers. Additionally, as the cold weather approaches and we’ll be spending more time indoors it’s worth taking a look at covid, what we should know and how to prepare for what’s to come.  

The Upward Trend is Clear 

It may seem as though Covid is affecting everyone again but according to an article published by ABC News, “COVID-19 has never really left us,” Dr. Graham Snyder, medical direction of infection prevention and hospital epidemiology at the University of Pittsburgh Medical Center said.” This uptick is a, “…steady churn pattern again where there’s a mix of variants and the variants are constantly changing and reemerging.” However, it’s hard to determine exactly how widespread the uptick is as the CDC, stopped recording aggregate covid case counts months ago.  

Should You be Masking? 

Mask mandates are no longer in effect; however, experts are saying it would be in your best interest to wear a mask in certain settings. In an article by The New York Times, Andrew Pekosz, a professor of molecular microbiology and immunology at the Johns Hopkins University Bloomberg School of Public Health stated, “I tend to say, if you’re going to go out, make sure you have a mask in your car, a couple masks at home or at work, so you always have something available to put on…” The main thing you should consider is your risk tolerance. If you are considered high-risk, you should consider masking when, “…you are in a relatively confined, crowded indoor space. That can include stores, offices and public transportation.” 

Types of Masks 

So now that we’ve established the fact that there is a covid surge here’s a refresher on what type of mask you should wear when masking. Linsey Marr, an expert in the airborne transmission of viruses at Virginia Tech told The New York Times that the type of masks you should wear are, “…N95, KN95 or KF94 masks, all of which filter out over 90 percent of virus particles, making them far more effective than surgical or cloth masks at reducing your chance of getting infected with Covid.”  

Masks should fit snuggly across your face and cover both your nose and mouth. 

The CDC has a list of resources for where to find free N95 masks.  

Jun 6, 2023

Despite COVID, Pharma Deals Set Records

Mega-deals were few last year, but pharmaceutical deal-making hit record levels. Nearly 2,000 transactions were recorded in 202 with a value of almost $200 billion.

One in five deals involved some aspect of COVID treatment or prevention, though these accounted for less than 3% of the total deal value,” says a new report from the biosciences intelligence group Cortellis. “Consistent with the historic trend, oncology remains the most attractive therapeutic area for deal making.”

A blockbuster year for biopharma deal making says that 2020 “ended up being a solid year for the biopharmaceutical industry. Records were broken by financing transactions, and several deals and M&As fell within the highest values on record.”

The biggest M&A deal was AbbVie’s $63 billion acquisition of Allergan. Though it closed during the year, the purchase was announced well before the SAR-CoV-2 virus first appeared. A second mega-deal — AstraZeneca’s buyout of Alexion Pharmaceuticals for $39 billion – was announced in December but won’t close until late this year.

However, most of the 147 M&A transactions were smaller, collectively totaling $181.3 billion, far below the banner $256 billion in 2015 and 19% below 2019. The report says “About 82% of the M&As were “bolt-ons” or those in which an acquirer was attaching itself to needed technology. The rest were financial, expansion and mega-deals.”

Though M&A activity was slower than in the past, the1,580 financing transactions were 42% higher than 2019. According to the report, “Collectively, global public and private biopharmaceutical companies raised approximately $134 billion, which is almost double the previous record of approximately $69 billion set in 2015. It is also greater than the combined amount generated in 2018 and 2019.”

The largest share of the global financings (70%) went to US companies, with firms based in California and Massachusetts capturing $34.1 billion and $26.8 billion, respectively. New York trailed the two leaders with $6.7 billion.

Summarizing the year, the report points to the “culture of collaboration that developed between competitors” driven by the need to develop COVID treatments and vaccines.

“It will be interesting to see whether this newfound enthusiasm for cooperation can be adapted to tackle other major unmet medical needs. Continued deal-making can only strengthen this collaborative spirit within the biopharma ecosystem, benefiting shareholders and patients alike.”

Photo by JOSHUA COLEMAN on Unsplash

[bdp_post_carousel]